Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Despite the enthusiasm Prime Minister Justin Trudeau tried to bring to his announcement Tuesday, when he said that Canada had struck a deal to manufacture millions of COVID-19 vaccines at home, the agreement won’t do much to get us out of the acute phase of this pandemic.

That’s because the deal with Novavax to churn out its vaccine at Canada’s National Research Council (NRC) in Montreal is contingent on the completion of a new production centre, which won’t be finished until summer or early fall. The facility will then need to be configured to the specifics of the Novavax vaccine and certified for production by Health Canada, which could take several months, meaning it won’t be until the end of 2021, earliest, that Canada can start producing the vaccine – months after the government’s promised September deadline of offering everyone who wants one a COVID-19 vaccine. It’s hard to get excited about Canadian-made vaccines that will be produced only after Canadians no longer need them.

Granted, the capacity to produce vaccines at home will be useful for future pandemics, or if COVID-19 variants require vaccine boosters. But there’s a third possibility that may justify the Novavax fanfare: perhaps despite the Prime Minister’s assurances, Canada is not on track for mass vaccinations by September, and maybe we will need those domestically produced Novavax vaccines after all.

Story continues below advertisement

COVID-19 news: Updates and essential resources about the pandemic

Can I travel out-of-province? Is my area in lockdown? A guide to COVID-19 restrictions across Canada

It’s a miserable scenario to contemplate, especially amid news that the U.K. is on track to vaccinate its entire population by mid-May, and reports that the U.S. will dispatch vaccines directly to pharmacies next week. Canada, meanwhile, is ranked 29th in the world for vaccinations per capita, and the government is grappling with reduced deliveries and the looming threat of European Union vaccine export controls (though the EU confirmed in a statement to CBC News that it has approved vaccine deliveries to Canada).

Canadians would nevertheless be justified in feeling anxious about our vaccine efforts, since the federal government has relied mostly on a “trust us” approach. Indeed, Ottawa has been extraordinarily secretive about many of the details of how and when vaccines will make their way to Canada, refusing to disclose delivery schedules agreed upon in purchasing contracts and ballpark figures of prices paid per dose. Other purchasers, by comparison, including the U.S. and the EU, have posted copies (albeit heavily redacted) of their vaccine agreements with various manufacturers.

Last week, the Prime Minister insisted that Canada has “always tried to be as transparent as possible” when sharing information about the country’s vaccination efforts. But when asked months ago, Mr. Trudeau was evasive about why Canada did not negotiate domestic manufacturing rights for the AstraZeneca vaccine. He suggested that Canada did not have capacity for domestic vaccine production even though upgrades of a NRC facility were already underway and despite the availability of private vaccine manufacturers such as Montreal-based PnuVax Inc.

Mr. Trudeau circled around the question when asked why his government chose to invest in foreign mRNA candidates rather than ones in production here at home, such as that by Providence Therapeutics, by simply stating that his government took the advice of its vaccine task force. And a few weeks ago, Procurement Minister Anita Anand wouldn’t even answer a straightforward question about whether the Prime Minister had personally been in touch with Pfizer’s CEO, even when asked directly by a reporter three times.

This country has a bizarre approach to access to information, where opacity is an impulse rather than a carefully considered last resort. It may be that certain specific details of Canada’s vaccine program cannot be released because of commercial confidentiality agreements with manufacturers, but if that is the case, Mr. Trudeau should come out and just say so. Yet that would not explain the government’s near-total refusal to speak to anything but the most general features of Canada’s vaccine-procurement efforts, which is most likely a symptom of the government’s preoccupation with micromanaging its communications. It is more politically advantageous, after all, to say next to nothing about Canada’s vaccine contracts and then – boom – announce millions of doses on their way alongside a picture of the Procurement Minister standing next to a plane.

Transparency won’t change the pace of vaccinations in Canada, but it will offer something of a framework for the future for people who have been navigating uncertainty for the better part of a year. And it was supposed to be the default position of a party that pledged to govern on a mantra of openness, access and disclosure. But listening to the Prime Minister string together talking points in response to specific questions about Canada’s vaccine program is evidence enough of how that’s going. Fingers crossed, I guess, for meeting that September deadline.

The large number of COVID-19 infections in some places makes it more likely for new variants of the virus to emerge. Science Reporter Ivan Semeniuk explains how vaccines may not be as effective against these new strains, making it a race to control and track the spread of variants before they become a dangerous new outbreak. The Globe and Mail

Keep your Opinions sharp and informed. Get the Opinion newsletter. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies